MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Cytokinetics, Incorporated (NASDAQ:CYTK)*
Organization & Developments: Cytokinetics
Parents
Cytokinetics, Incorporated (NASDAQ:CYTK)*
Children
*Company description: Develops pharmaceuticals aimed at treating disorders of the cytoskeleton.
*Cytokinetics and GlaxoSmithKline have entered into a broad strategic collaboration to discover, develop and commercialize novel small molecule therapeutics targeting mitotic kinesins for applications in the treatment of cancer and other diseases.
*Cytokinetics' R&D efforts aim to address pharmaceutical needs in cancer, cardiovascular and infectious diseases and feature proprietary Cytometrix cellular phenotyping technologies designed to industrialize cell biology for increased speed and productivity
*Developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
*Late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases
*The cytoskeleton is a complex, dynamic framework that impacts all aspects of cell function including cell division, cell motility, intracellular transport, muscle contractility and regulation of cellular organization.
*Total Patents Received: 155 (2010)
2018: After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII
2020: Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
2021: Will Small Biotech Stock Cytokinetics Undermine A Bristol Myers Buyout?
2022: Cytokinetics (CYTK) Investor Presentation - Slideshow_ seekingalpha.com
2022: Cytokinetics: 2 Catalysts For Heart Failure Drug Make This Worth A Look_ seekingalpha.com
2022: FDA Adcomm Votes Against Cytokinetics’ Heart Failure Drug
2022:Cytokinetics: Surprise AdComm For Omecamtiv Causing Concern_seekingalpha.com
2023: Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten_ seekingalpha.com
2023: Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)_ seekingalpha.com
2024: Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
2024: Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)_seekingalpha.com
2024: Cytokinetics, Incorporated: Buyout Speculation Persists
2024: Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities
2024: Cytokinetics: CEO Talks Down Buyout Prospects
2024: Cytokinetics: On The Cusp Of Commercialization
2024: Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes
2024: Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth
2024: Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds?
2025: Cytokinetics drug posts strong results in patients with heart condition
2025: Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten
2025: Cytokinetics: Derisked PDUFA Ahead, But Commercial Success Is The Question
2025: Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential
2025: Cytokinetics: Specialty Franchise With Aficamten And Ulacamten
Jumps
*Key People: Cytokinetics
Finance & Acquisitions: Cytokinetics